Sipuleucel-T Suspension for Intravenous Infusion (Provenge)

Elliott, William T.; Chan, James
June 2010
Internal Medicine Alert;6/15/2010, Vol. 32 Issue 11, p85
The article provides information on Sipuleucel-T vaccine, a cellular immunotherapy suggested to treat prostate cancer.


Related Articles

  • First cancer vaccine approved for use in people.  // New Scientist;5/8/2010, Vol. 206 Issue 2759, p5 

    The article discusses a prostate cancer vaccine called Provenge that has been approved by the U.S. Food and Drug Administration (FDA) for use in humans.

  • Unique Treatment Raises Tricky Bioethical Issues. Yard, Delicia Honen // Renal & Urology News;Aug2010, Vol. 9 Issue 8, p28 

    The article discusses tricky bioethical issues related to the treatment of prostate cancer. It mentions that despite the benefits of vaccine for advanced castration-resistant prostate cancer, the treatment is an extremely high cost. It tackles the bioethical issue of the Provenge, a treatment...

  • Castrate-resistant prostate cancer. Black, Peter // Oncology Exchange;Aug2011, Vol. 10 Issue 3, p9 

    The article discusses the development of various treatments for castrate-resistant prostate cancer (CPRC). It reviews some of the treatments in treating patients with CPRC which include abiratorine, denosumab, and zoledronic acid. It highlights various breakthroughs in managing CPRC that...

  • RESEARCH & TECHNOLOGY.  // MondayMorning;2/1/2010, Vol. 18 Issue 4, p4 

    The article offers updates related to research and technology in the U.S. A prostate cancer vaccine with smallpox virus helped cancer patients who are untreatable to live longer. Keryx Biopharmaceuticals Inc. affirms the effectiveness of its drug KRX-0401 in the survival of patients heavily...

  • Other News To Note.  // BioWorld International;4/3/2013, Vol. 18 Issue 14, p3 

    This section offers news briefs on biotechnology companies. CureVac GmbH announced the start of Phase IIb trial for its RNActive cancer vaccine CV9104 in subjects with castration-resistant prostate cancer. Oncodesign SA and Sanofi SA reached a deal for a second joint venture on kinase. South...

  • The evolving role of immunotherapy in prostate cancer. Gerritsen, W. R. // Annals of Oncology;Sep2012 Supplement 8, Vol. 23 Issue suppl_8, pviii22 

    The prognosis for men with metastatic, castration-resistant prostate cancer (CRPC) is limited, and patients have very few treatment options, particularly if the treatment failed with docetaxel (Taxotere). As a result, there is a requirement for novel approaches to therapy. Using immunotherapy to...

  • Prostate cancer vaccines: Update on clinical development. Geary, Sean M.; Salem, Aliasger K. // OncoImmunology;May2013, Vol. 2 Issue 5, pe24523-1 

    Prostate cancer is a common malignancy among elderly men and is essentially incurable once it becomes metastatic. Results from clinical trials testing a panel of specific vaccines in patients with castration-resistant prostate cancer (CRPC) suggest that alternative therapies may one day...

  • Novel agents in the management of castration resistant prostate cancer. Chaturvedi, Shruti; Garcia, Jorge A. // Journal of Carcinogenesis;2014, Vol. 13 Issue 1, p1 

    Prostate cancer (PCa) is a leading cause of cancer mortality in men and despite high cure rates with surgery and/or radiation, 30-40% of patients will eventually develop advanced disease. Androgen deprivation is the first line therapy for standard of care for men with advanced disease....

  • Sipuleucel-T. Higano, Celestia S.; Small, Eric J.; Schellhammer, Paul; Yasothan, Uma; Gubernick, Steven; Kirkpatrick, Peter; Kantoff, Philip W. // Nature Reviews Drug Discovery;Jul2010, Vol. 9 Issue 7, p513 

    In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. It is the first therapeutic cancer vaccine to receive FDA approval.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics